




SUPPLEMENTARY FIGURES




Supplementary Figure 1. Single cell RNA-seq analysis shows that IL-17D highly expresses in lung cancer cells, related to figure 1. (A) UMAP analysis shows transcriptionally differential clusters. Cells are colored by their 11 major cell types. (B) UMAP expression plots of known markers. (C) UMAP expression plots of *IL17D*. Scale bars represent z-score-normalized expression.




Supplementary Figure 2. IL-17D production in lung cancer cell lines was determined by ELISA, related to figure 1. Mean \pm SD. * $P < 0.05$. ** $P < 0.01$.



Supplementary Figure 3. Representative flow cytometry profiles of NK cells in CD45⁺ TILs in subcutaneous tumors, related to figure 3.



Supplementary Figure 4. IL-17D expression induces the release of CCL3 and CCL4 in A549 cell supernatants, related to figure 4. (A) CCL3 production was determined by ELISA in the supernatants of IL-17D-expressing and control A549 cells. (B) CCL4 production was determined by ELISA in the supernatants of IL-17D-expressing and control A549 cells. Mean \pm SD. * $P < 0.05$. ** $P < 0.01$.



Supplementary Figure 5. IL-17D does not affect phosphorylation of ERK protein, related to figure 5. Immunoblots show expression of ERK, p-ERK and β -actin in A549 cells transduced with IL17D or empty vector.